AAL

Analyst: This Drug Stock Could Surge 60%

RCKT shares have nearly doubled in 2018

Jul 10, 2018 at 2:13 PM
facebook X logo linkedin


The shares of Rocket Pharmaceuticals Inc (NASDAQ:RCKT) -- which specializes in rare disease therapies -- are higher today, thanks to some bullish analyst attention. Specifically, William Blair initiated coverage of RCKT stock with an "outperform" rating and a fair-value target of $32 -- representing expected upside of 63% from the security's close of $19.68 on Monday. The analyst wrote that Rocket Pharma has "ambitious goals for a relatively young company, [but] execution on this strategy could unlock significant value creation for shareholders."

Rocket Pharmaceuticals stock was last seen 3.9% higher to trade at $20.45. The company merged with Inotek Pharmaceuticals in early January, and has nearly doubled year-to-date, with pullbacks contained by its 80-day moving average. Further, RCKT stock today is set to end atop its 20-day moving average for the first time since June 20, when the shares were still lingering near annual-high territory.

RCKT stock chart july 10

An unwinding of short interest could also propel RCKT higher. Short interest jumped 52.2% during the past two reporting periods, and now accounts for more than 2 million Rocket Pharmaceuticals shares. At the security's average pace of trading, it would take more than six sessions to repurchase these pessimistic positions -- ample fuel for a short squeeze.

 

Same-Day Trading Power: +227% YTD and Counting  — Get in for $10!

We're celebrating 44 years of helping traders win, and you can now tap into one of our most explosive services — Dynamite Day Trading Signals — for just $10.

This service was built for one thing: capturing intraday gains with precision. 

Access two highly-vetted options trades each week -  Complete with defined entries, exits, and a clear plan for same-day profits.

👉 Click Here to Learn More and Position Yourself to Take Action When the Next Alert Hits.